Corcept Q2 revenue rises 19% to $194.4M; 2025 guidance raised to $850-900M

CORCEPT THERAPEUTICS INC

2025-Q2 EPS reported $0.46 revenue$351,644,000

Revenue $194.4M (+19% YoY); net income $35.1M vs $35.5M; diluted EPS $0.29 vs $0.32.
Modified 2025 revenue guidance to $850-900M; cash & investments $515M after $115.4M buyback.
NDA for relacorilant in hypercortisolism (PDUFA Dec 30, 2025); NDA submitted for ovarian cancer.
DAZALS: dazucorilant 300mg showed 84% reduced death risk (HR 0.16, p=0.0009); regulatory discussions.
Record new prescribers/patients; vendor capacity constraints offset demand; second pharmacy coming online.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.